# Tune Therapeutics

> Tune Therapeutics is a genetic-medicine company building tools to turn genes up or down without cutting DNA. Its TEMPO epigenetic-editing platform tunes gene expression the way a sound engineer rides a fader - reversible, programmable, and precise. Spun out of Duke's Gersbach Lab, Tune raised over $175M in Series B financing in January 2025 and is running first-in-human trials of TUNE-401, an epigenetic silencer for chronic hepatitis B, with the larger ambition of editing the genome's software to extend human healthspan.

- **Founded:** 2021
- **Headquarters:** Durham, North Carolina, United States
- **Founders:** Charles Gersbach (Co-Founder; Duke professor whose lab originated the platform), Fyodor Urnov (Co-Founder; Scientific Advisory Board), Akira Matsuno (Co-Founder; Chief Financial Officer)
- **Team size:** ~68 employees
- **Products:** TEMPO platform, TUNE-401, Epigenetic editing pipeline
- **Notable:** Raised over $175M Series B in January 2025, one of the largest rounds in epigenetic editing., Advanced TUNE-401 into first-in-human clinical trials for chronic hepatitis B (New Zealand and Hong Kong)., Spun out of Duke University's Gersbach Lab and reached the clinic within roughly five years.

## Products & services

- **TEMPO platform** — Proprietary epigenetic-editing (genetic tuning) platform that selectively activates, silences, or fine-tunes specific genes by modifying epigenetic marks rather than the DNA sequence itself, enabling reversible and multiplexed control of gene expression.
- **TUNE-401** — First-in-class epigenetic silencer for chronic hepatitis B (HBV). Designed to durably shut down viral gene expression with a single course; entered clinical trials in New Zealand and Hong Kong, with early Phase 1b/2a data reported in 2026.
- **Epigenetic editing pipeline** — Additional programs applying TEMPO to gene activation, cell reprogramming, regenerative medicine and age-related disease - aimed at conditions where dialing gene activity up or down is therapeutic.

## Achievements

- Raised over $175M Series B in January 2025, one of the largest rounds in epigenetic editing.
- Advanced TUNE-401 into first-in-human clinical trials for chronic hepatitis B (New Zealand and Hong Kong).
- Spun out of Duke University's Gersbach Lab and reached the clinic within roughly five years.
- Recruited John McHutchison (ex-Gilead CSO/Head of R&D, ex-Assembly Biosciences CEO) as CEO and Chairman.
- Reported early Phase 1b/2a clinical data for an epigenetic silencer at a major liver conference (EASL) in 2026.

## Latest updates

- **2026-05** — Reported early Phase 1b/2a clinical results for TUNE-401 epigenetic silencer around the EASL liver-disease congress.
- **2025-03** — Named John McHutchison, MD as CEO and Chairman of the Board, succeeding Matt Kane.
- **2025-01** — Completed over $175M Series B led by NEA, Yosemite, Regeneron Ventures and Hevolution Foundation.
- **2024-11** — Announced clearance to begin clinical trials of TUNE-401 in New Zealand, later expanding to Hong Kong.

## Links

- Website: https://tunetx.com
- LinkedIn: http://www.linkedin.com/company/tunetx
- Twitter/X: https://twitter.com/tunetx_news

---

Profile page: https://yespress.io/tune-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-20